Skip to main content
. Author manuscript; available in PMC: 2021 Jun 30.
Published in final edited form as: Biochem Biophys Res Commun. 2020 May 16;527(3):824–830. doi: 10.1016/j.bbrc.2020.04.124

Fig. 3.

Fig. 3.

Analysis of 62–66-week-old rAAV-G6PC-S298C-treated G6pc−/− mice. The data were analyzed from wild-type (+/+, n = 15), S298C/≥3% (n = 9) and S298C/<3% (n = 8) mice. When values between S298C/≥3% and S298C/<3% mice were similar, they were grouped together as the S298C (n = 17) mice. (A) Blood insulin levels. (B) Insulin tolerance profiles. (C) Hepatic metabolites values. (D) Hepatic levels of G6pt transcript. (E) Western-blot and densitometry analyses of hepatic GCK and β-actin. (F) The serum antibodies against human G6Pase-α. Lanes 1: anti-human G6Pase-α antiserum; lanes 2, 4, 6, 8, 10, 12: serum samples (1: 50 dilution) from wild-type mice, or lanes 3, 5, 7, 9, 11, 13: serum samples (1: 50 dilution) from rAAV-G6PCS298C-treated G6pc−/− mice. Numbers in parenthesis represent % of normal hepatic G6Pase-α activity restored in the mice. Data represent the mean ± SEM. *p< 0.05, **p< 0.005.